| Secondary |
| Product Used For Unknown Indication |
19.6% |
| Drug Use For Unknown Indication |
13.3% |
| Prophylaxis |
10.2% |
| Infection Prophylaxis |
9.3% |
| Constipation |
7.5% |
| Eczema |
5.0% |
| Hypertension |
4.3% |
| Compression Fracture |
3.6% |
| Upper Respiratory Tract Inflammation |
3.1% |
| Allergy Prophylaxis |
2.9% |
| Dry Skin Prophylaxis |
2.5% |
| Eczema Asteatotic |
2.5% |
| Hypokalaemia |
2.5% |
| Haemorrhoids |
2.3% |
| Chronic Respiratory Failure |
2.2% |
| Cough |
2.2% |
| Pyrexia |
2.0% |
| Trigeminal Neuralgia |
1.8% |
| Hepatitis C |
1.6% |
| Insomnia |
1.6% |
|
| Urinary Retention |
20.9% |
| Drug Interaction |
7.5% |
| Infective Exacerbation Of Chronic Obstructive Airways Disease |
7.5% |
| Cyanosis |
6.0% |
| Pseudomembranous Colitis |
6.0% |
| Toxic Epidermal Necrolysis |
6.0% |
| Tubulointerstitial Nephritis |
6.0% |
| Vomiting |
6.0% |
| Renal Failure |
4.5% |
| Anaphylactic Shock |
3.0% |
| Death |
3.0% |
| Drug Eruption |
3.0% |
| Eosinophilia |
3.0% |
| Rash |
3.0% |
| Renal Impairment |
3.0% |
| Stomatitis |
3.0% |
| Supraventricular Tachycardia |
3.0% |
| Tremor |
3.0% |
| Apnoeic Attack |
1.5% |
| Beta Haemolytic Streptococcal Infection |
1.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
47.1% |
| Drug Use For Unknown Indication |
14.1% |
| Chronic Obstructive Pulmonary Disease |
4.5% |
| Bronchitis |
4.5% |
| Rheumatoid Arthritis |
3.3% |
| Asthma |
3.0% |
| Hypertension |
3.0% |
| Prophylaxis |
3.0% |
| Pain |
2.5% |
| Constipation |
2.3% |
| Cough |
1.8% |
| Depression |
1.8% |
| Diabetes Mellitus |
1.5% |
| Emphysema |
1.4% |
| Retinal Detachment |
1.3% |
| Insomnia |
1.1% |
| Upper Respiratory Tract Inflammation |
1.0% |
| Glycogen Storage Disease Type Ii |
0.9% |
| Lower Respiratory Tract Infection |
0.9% |
| Parkinson's Disease |
0.9% |
|
| Water Intoxication |
12.6% |
| Vomiting |
8.3% |
| Pneumonia |
7.4% |
| White Blood Cell Count Increased |
7.0% |
| Wheezing |
6.5% |
| Thrombocytopenia |
6.1% |
| Treatment Failure |
5.2% |
| Electrocardiogram Qt Prolonged |
4.8% |
| Death |
4.3% |
| Pyrexia |
4.3% |
| Vocal Cord Paralysis |
4.3% |
| Hallucination |
3.9% |
| Malaise |
3.5% |
| Renal Failure Acute |
3.5% |
| Interstitial Lung Disease |
3.0% |
| Nausea |
3.0% |
| Oedema Peripheral |
3.0% |
| Rash |
3.0% |
| Sepsis |
3.0% |
| Skin Exfoliation |
3.0% |
|
| Interacting |
| Hypertension |
46.2% |
| Mycobacterial Infection |
30.8% |
| Atypical Mycobacterial Infection |
23.1% |
|
| Drug Interaction |
60.0% |
| Interstitial Lung Disease |
20.0% |
| Lung Disorder |
20.0% |
|
